<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557986</url>
  </required_header>
  <id_info>
    <org_study_id>MF07-01</org_study_id>
    <nct_id>NCT00557986</nct_id>
  </id_info>
  <brief_title>Local Surgery for Metastatic Breast Cancer</brief_title>
  <official_title>The Effect of Primary Surgical Treatment on Survival in Patients With Metastatic Breast Cancer at Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation of Breast Diseases Societies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abant Izzet Baysal University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federation of Breast Diseases Societies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary treatments for metastatic breast cancer are chemotherapy and radiation therapy, and
      surgery is reserved for tumor related complications such as bleeding. Retrospective studies
      showed that surgical removal of the primary tumor improves survival of patients with
      metastatic breast cancer at diagnosis. We hypothesis and testing that surgical removal of the
      primary tumor will lead to an improvement of overall survival
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, controled clinical trial. Our aim is to observe whether primary surgery
      improves survival in metastatic breast cancer. Women who have metastatic breast cancer at the
      initial diagnosis will be included in the study. There will be two study arms: primary
      surgery and systemic chemotherapy groups.

      In the primary surgery group patients will have adjuvant therapies after they had the proper
      surgery. In the systemic chemotherapy group patients will be followed after their initial
      therapy and will have surgery only if they have locoregional problems (such as wide necrosis
      or bleeding, etc). During the follow-up period, patients will be seen in every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: all cause mortality</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mordities</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Systemic Therapy only group (no primary surgery)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Surgery group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary surgery</intervention_name>
    <description>Primary breast surgery before systemic therapy</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with metastatic breast cancer at the initial diagnosis

        Exclusion Criteria:

          -  Women needs breast surgery at the time of initial diagnosis (such as bleeding,
             necrosis, etc)

          -  who have systemic morbidity that do not allows her to be in the trial,

          -  who have synchronous breast cancer at the contralateral breast,

          -  who have a previous cancer history or another primary cancer history and metastasis at
             the past,

          -  who have palpable lymph node/nodes at the contralateral axilla,

          -  who do not agree to participate the trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atilla Soran, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atilla Soran, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cukurova University</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Onkoloji Hastanesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adnan Menderes University</name>
      <address>
        <city>Aydin</city>
        <zip>09100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Izzet Baysal University</name>
      <address>
        <city>Bolu</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Medical faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara Univesity School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumhuriyet University Medical School</name>
      <address>
        <city>Sivas</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006 Jun 20;24(18):2743-9. Epub 2006 May 15.</citation>
    <PMID>16702580</PMID>
  </reference>
  <reference>
    <citation>Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK, Ross MI, Gwyn KM, Feig BW, Ames FC, Hortobagyi GN. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006 Jun;13(6):776-82. Epub 2006 Apr 17.</citation>
    <PMID>16614878</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>1-Metastatic breast cancer</keyword>
  <keyword>2-Surgery</keyword>
  <keyword>3-Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

